Article

Azelastine eye drops receive FDA approval

Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.

Key Points

Solna, Sweden-Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.

The substance azelastine is an antihistamine, and the eye-drop formulation is approved for treatment of allergic conjunctivitis in adults and children.

Meda is conducting a broad development program for the substance, both as eye drops and nasal spray. The azelastine eye drops sample is one part of that development.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.